NCT02996838View on ClinicalTrials.gov

A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 11, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Advanced Cancer
Interventions
DRUG

TQ-B3234

TQ-B3234 p.o. qd

Trial Locations (1)

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY